Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -0.11
- Piotroski Score 4.00
- Grade Speculative Buy
- Symbol (HBIO)
- Company Harvard Bioscience, Inc.
- Price $2.31
- Changes Percentage (5%)
- Change $0.11
- Day Low $2.18
- Day High $2.31
- Year High $5.56
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/06/2025
- Fiscal Year End N/A
- Average Stock Price Target $7.00
- High Stock Price Target $7.00
- Low Stock Price Target $7.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.20
- Trailing P/E Ratio -14.7
- Forward P/E Ratio -14.7
- P/E Growth -14.7
- Net Income $-3,415,000
Income Statement
Quarterly
Annual
Latest News of HBIO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Could Be 50% Below Their Intrinsic Value Estimate
Harvard Bioscience may be undervalued by 50% based on its current share price of US$2.88. Utilizing a Discounted Cash Flow (DCF) model, the intrinsic value was estimated at US$2.9, indicating potentia...
By Yahoo! Finance | 3 months ago -
Institutional investors may adopt severe steps after Harvard Bioscience, Inc.'s (NASDAQ:HBIO) latest 13% drop adds to a year losses
Institutional investors hold 65% of Harvard Bioscience, Inc. (NASDAQ:HBIO), influencing stock dynamics. Top 10 investors own 52%, with hedge funds and CEO James Green also holding significant stakes....
By Yahoo! Finance | 3 months ago
